{Reference Type}: Journal Article
{Title}: Recommendations for the management of gastrointestinal comorbidities with or without trofinetide use in rett syndrome.
{Author}: Motil KJ;Beisang A;Smith-Hicks C;Lembo A;Standridge SM;Liu E;
{Journal}: Expert Rev Gastroenterol Hepatol
{Volume}: 0
{Issue}: 0
{Year}: 2024 Jun 13
{Factor}: 4.095
{DOI}: 10.1080/17474124.2024.2368014
{Abstract}: <B>UNASSIGNED: </B>Although gastrointestinal (GI) comorbidities are experienced by over 90% of individuals with Rett syndrome (RTT), a neurodevelopmental disorder associated with mutations in the MECP2 gene, many neurologists and pediatricians do not rank the management of these comorbidities among the most important treatment goals for RTT. Trofinetide, the first approved pharmacologic treatment for RTT, confers improvements in RTT symptoms but is associated with adverse GI events, primarily diarrhea and vomiting. Treatment strategies for GI comorbidities and drug-associated symptoms in RTT represent an unmet clinical need.<BR><B>UNASSIGNED: </B>This perspective covers GI comorbidities experienced by those with RTT, either with or without trofinetide treatment. PubMed literature searches were undertaken on treatment recommendations for the following conditions: constipation, diarrhea, vomiting, aspiration, dysphagia, gastroesophageal reflux, nausea, gastroparesis, gastritis, and abdominal bloating.<BR><B>UNASSIGNED: </B>The authors recommend a proactive approach to management of symptomatic GI comorbidities and drug-associated symptoms in RTT to enhance drug tolerance and improve the quality of life of affected individuals. Management strategies for common GI comorbidities associated with RTT are reviewed based on authors' clinical experience and augmented by recommendations from the literature.